224 related articles for article (PubMed ID: 34282029)
1. Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer.
Falcomatà C; Bärthel S; Ulrich A; Diersch S; Veltkamp C; Rad L; Boniolo F; Solar M; Steiger K; Seidler B; Zukowska M; Madej J; Wang M; Öllinger R; Maresch R; Barenboim M; Eser S; Tschurtschenthaler M; Mehrabi A; Roessler S; Goeppert B; Kind A; Schnieke A; Robles MS; Bradley A; Schmid RM; Schmidt-Supprian M; Reichert M; Weichert W; Sansom OJ; Morton JP; Rad R; Schneider G; Saur D
Cancer Discov; 2021 Dec; 11(12):3158-3177. PubMed ID: 34282029
[TBL] [Abstract][Full Text] [Related]
2. p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.
Nagao M; Mizukoshi K; Nakayama S; Namikawa M; Hiramatsu Y; Maruno T; Nakanishi Y; Tsuruyama T; Fukuda A; Seno H
Oncotarget; 2023 Mar; 14():276-279. PubMed ID: 36999984
[No Abstract] [Full Text] [Related]
3. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous activation of Kras-Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway.
Namikawa M; Fukuda A; Mizukoshi K; Iwane K; Kawai M; Yamakawa G; Omatsu M; Sono M; Masuda T; Araki O; Nagao M; Yoshikawa T; Ogawa S; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Tsuruyama T; Taura K; Hatano E; Seno H
J Pathol; 2023 Aug; 260(4):478-492. PubMed ID: 37310065
[TBL] [Abstract][Full Text] [Related]
5. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.
Yang B; House MG; Guo M; Herman JG; Clark DP
Mod Pathol; 2005 Mar; 18(3):412-20. PubMed ID: 15467712
[TBL] [Abstract][Full Text] [Related]
10. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
Nakagawa H; Suzuki N; Hirata Y; Hikiba Y; Hayakawa Y; Kinoshita H; Ihara S; Uchino K; Nishikawa Y; Ijichi H; Otsuka M; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Tateishi K; Koike K
Proc Natl Acad Sci U S A; 2017 May; 114(19):E3806-E3815. PubMed ID: 28439013
[TBL] [Abstract][Full Text] [Related]
11. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
12. Biliary Tract Cancer: Molecular Biology of Precursor Lesions.
Manzano-Núñez F; Prates Tiago Aguilar L; Sempoux C; Lemaigre FP
Semin Liver Dis; 2023 Nov; 43(4):472-484. PubMed ID: 37944999
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
14. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
Bertuccio P; Malvezzi M; Carioli G; Hashim D; Boffetta P; El-Serag HB; La Vecchia C; Negri E
J Hepatol; 2019 Jul; 71(1):104-114. PubMed ID: 30910538
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
16. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
17. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
19. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.
Takemura Y; Ojima H; Oshima G; Shinoda M; Hasegawa Y; Kitago M; Yagi H; Abe Y; Hori S; Fujii-Nishimura Y; Kubota N; Masuda Y; Hibi T; Sakamoto M; Kitagawa Y
Cancer Med; 2021 Aug; 10(16):5599-5613. PubMed ID: 34245137
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Activation of Kras and Canonical Wnt Signaling Induces Premalignant Lesions That Progress to Extrahepatic Biliary Cancer in Mice.
Nagao M; Fukuda A; Omatsu M; Namikawa M; Sono M; Fukunaga Y; Masuda T; Araki O; Yoshikawa T; Ogawa S; Masuo K; Goto N; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Taketo MM; Ferrer J; Tsuruyama T; Nakanuma Y; Taura K; Uemoto S; Seno H
Cancer Res; 2022 May; 82(9):1803-1817. PubMed ID: 35247892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
